Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Liquidia Corp (NQ: LQDA )

13.74 +0.45 (+3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,591,139
Open 13.65
Bid (Size) 13.68 (7)
Ask (Size) 13.85 (2)
Prev. Close 13.29
Today's Range 13.31 - 14.00
52wk Range 5.710 - 16.99
Shares Outstanding 76,793,694
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings For Liquidia
Via Benzinga
LQDA Stock Earnings: Liquidia Misses EPS, Misses Revenue for Q2 2024
LQDA stock results show that Liquidia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+19.17%
+19.17%
1 Month
+10.45%
+10.45%
3 Month
+11.80%
+11.80%
6 Month
-7.16%
-7.16%
1 Year
+97.13%
+97.13%

More News

Read More
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
From Liquidia Corporation
Via GlobeNewswire
Expert Outlook: Liquidia Through The Eyes Of 5 Analysts
Via Benzinga
Forecasting The Future: 5 Analyst Projections For Liquidia
Via Benzinga
7 Analysts Have This To Say About Liquidia
Via Benzinga
Liquidia Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
From Liquidia Corporation
Via GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
The Analyst Landscape: 5 Takes On Liquidia
Via Benzinga
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
From Liquidia Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
LQDA Stock Earnings: Liquidia Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
From Liquidia Corporation
Via GlobeNewswire
Jim Cramer: You're 'Dice Rolling' With This Biopharma Stock, But Vista Energy Is 'A Good Situation'
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
From Liquidia Corporation
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.